Sensonics received the CE mark for its next-generation E3 CGM with plans to launch in the third quarter. It will be facing stiff competition from CGM makers Dexcom and Abbott in the European market. 

Japan's national health insurance scheme will reimburse infertility treatments from April 2022, in a bid to make the treatments more accessible to patients by effectively lowering the cost by 70%. The key strategic aim is to raise a low birth rate and the move is also set to substantially expand the market for such products for both domestic and foreign players.

Prostate cancer patients press HHS for administrative hearing on march-in rights for patents covering Astellas’ Xtandi. While previous efforts have failed, petitioners believe they may have a shot this time around given Biden Administration and HHS Secretary Becerra’s views on the issue.

Nandini Piramal, executive director of Piramal Enterprises, discusses how things have shaped the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing "framework" deployed by industry.